Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Antaxone
2. Celupan
3. En 1639a
4. En-1639a
5. En1639a
6. Nalorex
7. Naltrexone
8. Nemexin
9. Revia
10. Trexan
1. Naltrexone Hcl
2. 16676-29-2
3. Trexan
4. Depade
5. Antaxone
6. Revia
7. Naltrexone (hydrochloride)
8. En-1639a
9. Nih 8503
10. Celupan
11. Nemexin
12. N-cyclopropylmethyl-noroxymorphone Hydrochloride
13. Mls000069607
14. Naltrexone Hydrochloride [usp]
15. Z6375yw9sf
16. Vivitrex
17. 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
18. Nalorex
19. Smr000058767
20. En-1639a (as Hydrochloride)
21. En 1639a
22. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
23. Naltrexone Hydrochloride (usp)
24. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one Hydrochloride
25. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride (1:1), (5alpha)-
26. Ccris 1168
27. Einecs 240-723-0
28. Unii-z6375yw9sf
29. Naltrel
30. Naltrexone.hcl
31. Naltrexone Depot
32. Prestwick_348
33. Mfcd00069324
34. (5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
35. Revia (tn)
36. Xr-ntx
37. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride
38. Opera_id_1828
39. Naltrexone Monohydrochloride
40. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-, Hydrochloride
41. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5-alpha)-
42. Schembl37713
43. Mls001076516
44. Mls002153483
45. Mls002695940
46. Cyto-205
47. Chembl1201149
48. Dtxsid50937236
49. Pti-901
50. Chebi:134687
51. Bcp08343
52. Naltrexone Hydrochloride [mi]
53. S2103
54. Vp-004
55. Akos015994597
56. Ccg-268383
57. Cs-0763
58. Hs-0003
59. Nc00693
60. 17-cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
61. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-oxy-3,14-dihydoxy-, Hydrochloride
62. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5alpha)-
63. Naltrexone Hydrochloride [mart.]
64. Naltrexone Hydrochloride [vandf]
65. Naltrexone Hydrochloride [who-dd]
66. Bn164635
67. Hy-76710
68. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, Hydrochloride, (5.alpha.)-
69. N1176
70. Naltrexone Hydrochloride [green Book]
71. Sw196619-3
72. Naltrexone Hydrochloride [orange Book]
73. D02095
74. Embeda Component Naltrexone Hydrochloride
75. H10489
76. Naltrexone Hydrochloride [ep Monograph]
77. Naltrexone Hydrochloride [usp Monograph]
78. Troxyca Component Naltrexone Hydrochloride
79. 676n292
80. Contrave Component Naltrexone Hydrochloride
81. Naltrexone Hydrochloride Component Of Embeda
82. Naltrexone Hydrochloride Component Of Troxyca
83. Naltrexone Hydrochloride Component Of Contrave
84. Q27096434
85. Z1558290144
86. Naltrexone Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
87. Naltrexone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
88. (5a)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-morphinan-6-one Hydrochloride
89. 17-(cyclopropylmethyl)-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one Hydrochloride
90. 17-cyclopropylmethyl)-4,5.alpha.-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
91. (1s,5r,13r,17s)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one Hydrochloride
92. (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydron;chloride
93. (5alpha,17r)-17-(cyclopropylmethyl)-3,14-dihydroxy-6-oxo-4,5-epoxymorphinan-17-ium Chloride
94. Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-, Hydrochloride (1:1)
Molecular Weight | 377.9 g/mol |
---|---|
Molecular Formula | C20H24ClNO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 377.1393859 g/mol |
Monoisotopic Mass | 377.1393859 g/mol |
Topological Polar Surface Area | 70 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 621 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
2 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
3 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
4 of 6 | |
---|---|
Drug Name | Naltrexone hydrochloride |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | Naltrexone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethy... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg; 100mg; 50mg |
Market Status | Prescription |
Company | Accord Hlthcare; Mallinckrodt; Sun Pharma Global; Elite Labs; Barr |
5 of 6 | |
---|---|
Drug Name | Revia |
PubMed Health | Naltrexone |
Drug Classes | Ethanol Dependency, Opioid Dependency, Toxicology-Antidote Agent |
Drug Label | REVIA (naltrexone hydrochloride tablets USP), an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced... |
Active Ingredient | Naltrexone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 50mg |
Market Status | Prescription |
Company | Teva Womens |
6 of 6 | |
---|---|
Drug Name | Vivitrol |
Active Ingredient | Naltrexone |
Dosage Form | For suspension, extended release |
Route | Intramuscular |
Strength | 380mg/vial |
Market Status | Prescription |
Company | Alkermes |
Alcohol Deterrents
Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism. (See all compounds classified as Alcohol Deterrents.)
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 20623
Submission : 2007-06-20
Status : Active
Type : II
Certificate Number : CEP 2009-287 - Rev 03
Issue Date : 2024-03-01
Type : Chemical
Substance Number : 1790
Status : Valid
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2019-05-30
Registration Number : 20190530-209-J-359
Manufacturer Name : Sanofi Winthrop Industrie
Manufacturer Address : Route d'Avignon 30390 Aramon, France
Available Reg Filing : CN |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
NDC Package Code : 50396-6008
Start Marketing Date : 2013-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Product Not Available For Sales
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-06-16
Pay. Date : 2012-12-20
DMF Number : 15102
Submission : 2000-10-18
Status : Active
Type : II
NDC Package Code : 60870-0395
Start Marketing Date : 1990-01-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Certificate Number : R1-CEP 2016-053 - Rev 00
Issue Date : 2023-01-13
Type : Chemical
Substance Number : 1790
Status : Valid
Date of Issue : 2025-02-11
Valid Till : 2027-06-09
Written Confirmation Number : WC-0278
Address of the Firm :
NDC Package Code : 70312-0887
Start Marketing Date : 2015-12-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Phamchem Service Co., Ltd.
Registration Date : 2023-10-16
Registration Number : 20210611-209-J-542(2)
Manufacturer Name : Rusan Pharma Ltd.
Manufacturer Address : Plot no. 6406, GIDC ESTATE, ANKLESHWAR, City : ANKLESHWAR - 393 002, Dist : Bharuch, Gujarat State, India
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
NDC Package Code : 45085-0292
Start Marketing Date : 2024-08-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-14
Pay. Date : 2013-12-20
DMF Number : 23325
Submission : 2009-12-01
Status : Active
Type : II
Certificate Number : CEP 2020-291 - Rev 02
Issue Date : 2024-04-23
Type : Chemical
Substance Number : 1790
Status : Valid
NDC Package Code : 51634-1064
Start Marketing Date : 2024-01-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 20623
Submission : 2007-06-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-06-16
Pay. Date : 2012-12-20
DMF Number : 15102
Submission : 2000-10-18
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-12-20
DMF Number : 23325
Submission : 2009-12-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-05
Pay. Date : 2012-11-27
DMF Number : 6265
Submission : 1986-04-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21820
Submission : 2008-07-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-16
Pay. Date : 2013-01-28
DMF Number : 23214
Submission : 2009-10-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-22
Pay. Date : 2021-12-03
DMF Number : 36560
Submission : 2022-03-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21217
Submission : 2007-12-28
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41264
Submission : 2025-06-20
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Certificate Number : CEP 2009-287 - Rev 03
Status : Valid
Issue Date : 2024-03-01
Type : Chemical
Substance Number : 1790
Certificate Number : R1-CEP 2016-053 - Rev 00
Status : Valid
Issue Date : 2023-01-13
Type : Chemical
Substance Number : 1790
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Naltrexone Hydrochloride, Wavelength Site
Certificate Number : CEP 2020-291 - Rev 02
Status : Valid
Issue Date : 2024-04-23
Type : Chemical
Substance Number : 1790
Certificate Number : CEP 2018-218 - Rev 02
Status : Valid
Issue Date : 2024-11-20
Type : Chemical
Substance Number : 1790
Certificate Number : R1-CEP 2006-117 - Rev 02
Status : Valid
Issue Date : 2017-05-05
Type : Chemical
Substance Number : 1790
Certificate Number : CEP 2017-313 - Rev 02
Status : Valid
Issue Date : 2024-06-12
Type : Chemical
Substance Number : 1790
Certificate Number : R1-CEP 2009-352 - Rev 03
Status : Valid
Issue Date : 2023-02-15
Type : Chemical
Substance Number : 1790
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
NDC Package Code : 50396-6008
Start Marketing Date : 2013-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
NDC Package Code : 52465-103
Start Marketing Date : 2013-12-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0395
Start Marketing Date : 1990-01-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 70312-0887
Start Marketing Date : 2015-12-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
NDC Package Code : 45085-0292
Start Marketing Date : 2024-08-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
NDC Package Code : 51634-1064
Start Marketing Date : 2024-01-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-0737
Start Marketing Date : 2004-09-01
End Marketing Date : 2026-02-28
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 65724-0054
Start Marketing Date : 2019-02-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 10695-114
Start Marketing Date : 2025-01-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 10695-132
Start Marketing Date : 2025-01-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Contrave, also marketed as Mysimba is an extended release fixed dose combination of naltrexone HCL/bupropion HCL indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Lead Product(s): Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area: Nutrition and Weight Loss Brand Name: Contrave
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 18, 2023
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Contrave®/Mysimba® Demonstrates No Increased Risk in Major Adverse Cardiac Events in A Large, Lo...
Details : Contrave, also marketed as Mysimba is an extended release fixed dose combination of naltrexone HCL/bupropion HCL indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Product Name : Contrave
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2023
Details:
Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Hamden Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Details : Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2022
Details:
Phase 1 clinical trial data showed that SP-104 (naltrexone hydrochloride) treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-104
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 1 clinical trial data showed that SP-104 (naltrexone hydrochloride) treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.
Product Name : SP-104
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2022
Details:
Statera will receive milestones, new indications and royalties, Crohn’s disease and COVID-19 indications and regulatory approvals, payments from Immune Therapeutics in exchange for Statera’s rights to any product containing low-dose naltrexone as an active ingredient.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: STAT-205
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Immune Therapeutics
Deal Size: $402.0 million Upfront Cash: $2.0 million
Deal Type: Agreement April 27, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Immune Therapeutics
Deal Size : $402.0 million
Deal Type : Agreement
Details : Statera will receive milestones, new indications and royalties, Crohn’s disease and COVID-19 indications and regulatory approvals, payments from Immune Therapeutics in exchange for Statera’s rights to any product containing low-dose naltrexone as an ...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
April 27, 2022
Details:
The Part A of the trial evaluated three dose levels of PF614 showed positive review from the Phase 1b tria, independent Safety Review Committee allowed the trial to proceed to the next dose level.
Lead Product(s): Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: PF614
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2022
Lead Product(s) : Oxycodone Prodrug,Nafamostat,Naltrexone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Part A of the trial evaluated three dose levels of PF614 showed positive review from the Phase 1b tria, independent Safety Review Committee allowed the trial to proceed to the next dose level.
Product Name : PF614
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 01, 2022
Details:
STAT-205 may show promise in treating both acute COVID infections and long COVID in this manner. Preliminary in vitro data demonstrated the drug’s ability to slow or halt the progression of SARS-CoV-2 (the virus that causes COVID-19) in human lung cells.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: STAT-205
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STAT-205 may show promise in treating both acute COVID infections and long COVID in this manner. Preliminary in vitro data demonstrated the drug’s ability to slow or halt the progression of SARS-CoV-2 (the virus that causes COVID-19) in human lung cell...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2022
Details:
LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries.
Lead Product(s): Baclofen,Naltrexone Hydrochloride,Sorbitol
Therapeutic Area: Musculoskeletal Brand Name: Lyvispah
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2022
Lead Product(s) : Baclofen,Naltrexone Hydrochloride,Sorbitol
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spina...
Details : LYVISPAH is bioequivalent to oral baclofen tablets and provides flexible, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries.
Product Name : Lyvispah
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Details:
CX-101 is an investigational drug that is being studied for smoking cessation.The Phase 3 program builds on the successful Phase 2b findings and evaluates a mixed-weight population at a fixed-dose combination of CX-101 (naltrexone/bupropion 32 mg/360 mg total daily dose).
Lead Product(s): Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Contrave
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2021
Lead Product(s) : Naltrexone Hydrochloride,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-101 is an investigational drug that is being studied for smoking cessation.The Phase 3 program builds on the successful Phase 2b findings and evaluates a mixed-weight population at a fixed-dose combination of CX-101 (naltrexone/bupropion 32 mg/360 mg ...
Product Name : Contrave
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2021
Details:
During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells. Data also shows that STAT-205 could prevent life-threatening lung inflammation caused by COVID-19, as well as lessen the risk of reinfection.
Lead Product(s): Naltrexone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: STAT-205
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2021
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells. Data also shows that STAT-205 could prevent life-threatening lung inflammation caused by COVID-19, as well as lessen th...
Product Name : STAT-205
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
CAS Number : 7051-34-5
End Use API : Naltrexone Hydrochloride
About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...
CAS Number : 7051-34-5
End Use API : Naltrexone Hydrochloride
About The Company : Integrated solutions for all your projects.
M2i Group provides integrated solutions for all your projects. We offer our clients an integrated partner, fr...
RLD : No
TE Code : AB
Brand Name : NALTREXONE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2011-08-17
Application Number : 91205
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Brand Name : EMBEDA
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2009-08-13
Application Number : 22321
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Brand Name : EMBEDA
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2009-08-13
Application Number : 22321
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Brand Name : EMBEDA
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2009-08-13
Application Number : 22321
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Brand Name : EMBEDA
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2009-08-13
Application Number : 22321
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE
Brand Name : EMBEDA
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2009-08-13
Application Number : 22321
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Brand Name : NALTREXONE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2017-07-21
Application Number : 207905
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE
Brand Name : CONTRAVE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 90MG;8MG
Approval Date : 2014-09-10
Application Number : 200063
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Brand Name : TROXYCA ER
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 1.2MG;10MG
Approval Date : 2016-08-19
Application Number : 207621
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
Brand Name : TROXYCA ER
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 2.4MG;20MG
Approval Date : 2016-08-19
Application Number : 207621
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Naltrexone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naltrexone Hydrochloride manufacturer or Naltrexone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Naltrexone Hydrochloride API Price utilized in the formulation of products. Naltrexone Hydrochloride API Price is not always fixed or binding as the Naltrexone Hydrochloride Price is obtained through a variety of data sources. The Naltrexone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Naltrexone HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naltrexone HCl, including repackagers and relabelers. The FDA regulates Naltrexone HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naltrexone HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Naltrexone HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Naltrexone HCl supplier is an individual or a company that provides Naltrexone HCl active pharmaceutical ingredient (API) or Naltrexone HCl finished formulations upon request. The Naltrexone HCl suppliers may include Naltrexone HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Naltrexone HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Naltrexone HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Naltrexone HCl active pharmaceutical ingredient (API) in detail. Different forms of Naltrexone HCl DMFs exist exist since differing nations have different regulations, such as Naltrexone HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Naltrexone HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Naltrexone HCl USDMF includes data on Naltrexone HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Naltrexone HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Naltrexone HCl suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Naltrexone HCl Drug Master File in Korea (Naltrexone HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Naltrexone HCl. The MFDS reviews the Naltrexone HCl KDMF as part of the drug registration process and uses the information provided in the Naltrexone HCl KDMF to evaluate the safety and efficacy of the drug.
After submitting a Naltrexone HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Naltrexone HCl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Naltrexone HCl suppliers with KDMF on PharmaCompass.
A Naltrexone HCl CEP of the European Pharmacopoeia monograph is often referred to as a Naltrexone HCl Certificate of Suitability (COS). The purpose of a Naltrexone HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Naltrexone HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Naltrexone HCl to their clients by showing that a Naltrexone HCl CEP has been issued for it. The manufacturer submits a Naltrexone HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Naltrexone HCl CEP holder for the record. Additionally, the data presented in the Naltrexone HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Naltrexone HCl DMF.
A Naltrexone HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Naltrexone HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Naltrexone HCl suppliers with CEP (COS) on PharmaCompass.
A Naltrexone HCl written confirmation (Naltrexone HCl WC) is an official document issued by a regulatory agency to a Naltrexone HCl manufacturer, verifying that the manufacturing facility of a Naltrexone HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Naltrexone HCl APIs or Naltrexone HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Naltrexone HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Naltrexone HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Naltrexone HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Naltrexone HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Naltrexone HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Naltrexone HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Naltrexone HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Naltrexone HCl suppliers with NDC on PharmaCompass.
Naltrexone HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naltrexone HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naltrexone HCl GMP manufacturer or Naltrexone HCl GMP API supplier for your needs.
A Naltrexone HCl CoA (Certificate of Analysis) is a formal document that attests to Naltrexone HCl's compliance with Naltrexone HCl specifications and serves as a tool for batch-level quality control.
Naltrexone HCl CoA mostly includes findings from lab analyses of a specific batch. For each Naltrexone HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naltrexone HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Naltrexone HCl EP), Naltrexone HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naltrexone HCl USP).